Gain Therapeutics (GANX) stock

Market cap $75.1M

$1.71

-0.58%

Market closed. Prices as of today's close.

Quality Score

-2

Poor

In its industry

#167of 300

Biotech

Checks firing

4of 14

Choppy

From 52-week high

-60.6%

Below the 200-day

NextQ4 2026“Final results from Phase 1b clinical study of rexaceract expected in Q4 2026.”Trial data · 8-K, Aug 11

Cash$13.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into the second quarter of 2027”

Follow GANX's trial news. Pro members can get an alert when Gain Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when GANX files news on its trialsFree for 24 hours. No account needed.

Cash$13.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into the second quarter of 2027”

Pipeline and cash

What's next for GANX, and how long its cash lasts

From Gain Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q4 2026“Final results from Phase 1b clinical study of rexaceract expected in Q4 2026.”Trial data · 8-K, Aug 11

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseasePhase 2 · Not yet recruiting · 111 people · main data estimated Jun 30, 2028 · NCT07280299

1 more trial, 46 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 2 quarters

$13.1M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into the second quarter of 2027” (8-K, Jul 16).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 28, 2025)
At-the-market share sales program (424B5, filed Nov 28, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Gene Mack buys or sells

For Pro members: every trade, and Gene Mack’s 8 filings and quotes.

Get an optional alert when GANX files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $125MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $123MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $520MDrug not namedUnder FDA review

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why GANX scores -2

PoorChoppy, 4 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+4Chart checks 4 of 14 firing right now, one point each
−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years

Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Run-up, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on GANX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:46 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, after the close

After its last 4 reports it closed 0.0% on average, higher 2 of 4 times.

What would turn GANX's score around: 6 things, for Pro members

Alert me when GANX's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock has a live page like this, GANX included: the price in real time, the full chart, all 14 checks, and every line of its score.

AMD's page for Pro members on a phone, recorded live: the price changes as it trades, beside its Quality Score and its rank, with the bid and ask under it and a year of candles below — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

A Pro member's stock page for AMD: its Quality Score with its rank and the line driving it, the live price with the bid and ask, the chart checks, strength, and next earnings, and a year of candles with the 21 and 50-day averages and the Quality Score drawn under the chart — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

The Score tab on a phone: how AMD's Quality Score adds up from price action, the company, and signals, its rank, and the chart checks by group, trend, volume, tight range, and buying — Every line of the scoreWhat each part adds, and all 14 checks by group, on GANX and every other stock.

The New alert form on a phone: watch one name, AMD, when its Quality Score is at least 20, sent by the bell on the site, a push notification, and email, with the Save alert button — Your own optional alertsPick what to watch, GANX or your whole watchlist, and when: a Quality Score, a price, a filing. It comes by push, email, or the bell.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

The 14 checks

GANX has 4 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on GANX, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1443.3
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 3 sessions ago.
50-day average$1.83
The price is 6.6% below it.
200-day average$2.01
The price is 14.9% below it. The 50-day is below the 200-day, since Mar 24.
ADX 1412.0
Under 25, with +DI above -DI.
Support$1.69
Swing low from Sep 10, 1.2% below the price.
Resistance$1.85
Swing high from Sep 8, 8.2% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $1.64 to $1.90.
Volume0.9x
Against its 20-day average, for the time of day.

Its industry

How GANX ranks in Biotech

GANX is #167 of 300 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2EXELExelixis7/1417
3AMRXAmneal Pharmaceuticals6/1417
FHTXFoghorn TherapeuticsOpen for its score
FULCFulcrum TherapeuticsOpen for its score
GILDGilead SciencesOpen for its score
GOSSGossamer BioOpen for its score
167GANXGain Therapeutics4/14-2

When does GANX report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 40 days). Not yet confirmed by the company.

+1.4%-3.2%-1.1%+2.9%

Nov 12Mar 26May 11Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026After close	After close	-2.4%	+2.9%	-1.5%
May 11, 2026After close	After close	-1.1%	-1.1%	-11.0%
Mar 26, 2026After close	After close	+0.5%	-3.2%	-2.1%
Nov 12, 2025After close	After close	-0.7%	+1.4%	-6.8%

The gap is the next open against the close before the report; the reaction is where that session closed. GANX closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About Gain Therapeutics

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

21 employeesBethesda, MDgaintherapeutics.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of GANX's score, with the points and the reason
All 14 checks on GANX and on all 3,243 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on GANX

See all 14 checks on GANXFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.